Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1627 1629
This examiner grants 61% of resolved cases
Sophia Jane Reilly serves as an examiner in Tech Center 1600 and Art Unit 1627. She has a total of 74 resolved cases. The allowance rate for these cases is 60.8 percent. This 60.8 percent rate indicates the frequency at which applications reach a grant under her review. With 74 resolved cases, the profile provides a specific look at the outcomes in this docket.
The interview lift is 49.2 percent. This 49.2 percent figure is lower than the 60.8 percent allowance rate, but it represents a significant increase in the likelihood of allowance for cases that include an interview. Practitioners in Art Unit 1627 may use this 49.2 percent lift to evaluate the impact of direct communication. The median days to allowance is 1225. This 1225-day duration is the typical timeframe for successful applications. The 1225-day metric, combined with the 74 resolved cases, helps stakeholders understand the pendency and probability of success in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17928496 | COMPOSITIONS AND METHODS FOR TREATING VIRUS INFECTION | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18033178 | METHODS TO SENSITIZE TUMORS TO TREATMENT BY IMMUNOTHERAPY | Non-Final OA | Ohio State Innovation Foundation |
| 18730214 | IMMUNOMODULATORY LIPIDS AND USES THEREOF | Non-Final OA | The General Hospital Corporation |
| 18800559 | COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK | Non-Final OA | Novartis AG |
| 18800769 | SULFONATO RESORCINARENE-COMPLEXED FLUOROQUINOLONES AND METHODS OF USE | Non-Final OA | University of Cincinnati |
| 18844654 | COMBINATION THERAPIES FOR BREAST CANCER | Non-Final OA | Hoffmann-La Roche Inc. |
| 18802257 | PROCESSES FOR THE PREPARATION OF 1,2,3,5,6,7-HEXAHYDRO-S-INDACENE DERIVATAIVES | Non-Final OA | Hoffmann-La Roche Inc. |
| 18068407 | AMIDOPYRIMIDONE DERIVATIVES | Non-Final OA | Hoffmann-La Roche Inc. |
| 18691686 | MYCOBACTERIUM ABSCESSUS GROWTH INHIBITOR AND MODEL | Non-Final OA | Nanyang Technological University |
| 17919726 | COMBINATION THERAPY OF ARTEMISININ-RELATED COMPOUNDS AND HISTONE DEACETYLASE INHIBITORS FOR TREATMENT OF HPV-RELATED BENIGN, PREMALIGNANT, AND MALIGNANT DISEASES | Final Rejection | Georgetown University |
| 18858168 | MODULATORS OF INTRACELLULAR CHLORIDE CONCENTRATION FOR USE IN THE TREATMENT OF COGNITIVE DECLINE | Non-Final OA | FONDAZIONE TELETHON ETS |
| 18220090 | INHIBITORS OF THE PLASMODIAL SURFACE ANION CHANNEL AS ANTIMALARIALS | Non-Final OA | The United States of America,as represented by the Secretary,Department of Health and Human Services |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy